SCHEMBL3222210

SCHEMBL3222210

N#Cc1cc(Cl)cc(Oc2cc(CCc3ccccc3)[nH]c(=O)c2Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 8/20 0.41
CYP3A4 P08684 3/20 0.36
KCNH2 Q12809 2/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
GPR84 Q9NQS5 1/20 0.36
VEGFA P15692 2/20 0.34
EPAS1 Q99814 2/20 0.34
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34
TUBB4B P68371 1/20 0.34
TUBB3 Q13509 1/20 0.34
TUBB2A Q13885 1/20 0.34
TUBB8 Q3ZCM7 1/20 0.34
TUBA3E Q6PEY2 1/20 0.34
TUBA1A Q71U36 1/20 0.34
TUBA1C Q9BQE3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3208870 0.92 DAO (0.47) DAOCYP3A4KCNH2CYP2D6CYP2C9
SCHEMBL3205327 0.90 DAO (0.40) DAOCYP3A4KCNH2GPR84VEGFA
SCHEMBL13457908 0.90 DAO (0.40) DAOGPR84EPAS1TUBB4ATUBB
SCHEMBL3220872 0.90 DAO (0.40) DAOCYP3A4KCNH2CYP2D6CYP2C9
SCHEMBL3218219 0.89 GPR84 (0.41) DAOCYP3A4KCNH2CYP2D6CYP2C9
SCHEMBL3213769 0.88 CYP19A1 (0.41) DAOCYP3A4KCNH2CYP2D6CYP2C9
SCHEMBL3201588 0.85 CYP11B1 (0.37) DAOCYP3A4KCNH2CYP2D6CYP2C9
SCHEMBL13458259 0.84 DAO (0.42) DAOGPR84TUBB4ATUBBTUBA3C
SCHEMBL3208890 0.83 GRM5 (0.41) DAOCYP3A4KCNH2CYP2D6CYP2C9
SCHEMBL3210112 0.81 RAB9A (0.39) CYP3A4KCNH2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010026075-A1 PYRIDINE DERIVATIVES AS INHIBITORS OF HIV-I REVERSE TRANSCRIPTASE F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 WO claimed
US-20100056535-A1 Inhibitors of HIV-1 reverse transcriptase ROCHE PALO ALTO LLC 2010-03-04 US claimed
WO-2010026075-A1 PYRIDINE DERIVATIVES AS INHIBITORS OF HIV-I REVERSE TRANSCRIPTASE F. HOFFMANN-LA ROCHE AG (CH) 2010-03-11 WO disclosed
US-20100056535-A1 Inhibitors of HIV-1 reverse transcriptase ROCHE PALO ALTO LLC 2010-03-04 US disclosed
US-20100056535-A1 Inhibitors of HIV-1 reverse transcriptase ROCHE PALO ALTO LLC 2010-03-04 US disclosed
US-20100056535-A1 Inhibitors of HIV-1 reverse transcriptase ROCHE PALO ALTO LLC 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056535-A1 Inhibitors of HIV-1 reverse transcriptase QTRT1, NQO2, QTRT2 DAO 1380/4885CYP3A4 1165/4885KCNH2 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.